Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASLTS:0DZ0 +2.91%90 Cash Ratio is 2.29 as of Jun. 2026, which is 11% above its 10-year median of 2.06. GuruFocus rates LTS:0DZ0 with a GF Score™ of 90/100 and a GF Value™ of kr520.57 (Fairly Valued). The stock has 3 warning signs investors should review. Among 834 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 72.78% on this metric.
ChemoMetec AS has a Cash Ratio of 2.29. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for ChemoMetec AS's Cash Ratio or its related term are showing as below:
LTS:0DZ0'
s Cash Ratio Range Over the Past 10 Years
Min: 0.55 Med: 2.06 Max: 3.01
Current: 2.29
During the past 13 years, ChemoMetec AS's highest Cash Ratio was 3.01. The lowest was 0.55. And the median was 2.06.
LTS:0DZ0's Cash Ratio is ranked better than 72.78% of 834
companies
in the Medical Devices & Instruments industry
Industry Median: 0.945
vs LTS:0DZ0: 2.29
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ChemoMetec AS Cash Ratio Related Terms
ChemoMetec AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ChemoMetec AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (LTS:0DZ0) has a Cash Ratio of 2.29 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ChemoMetec AS and its competitors. This is 11% above median its historical median of 2.06. Over the past decade, ChemoMetec AS's Cash Ratio has ranged from 0.55 to 3.01. According to the industry distribution chart, ChemoMetec AS ranks #227 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 27.2%.
Is ChemoMetec AS's Cash Ratio too high?
ChemoMetec AS's current Cash Ratio of 2.29 is 11% above median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 3.01. The Medical Devices & Instruments industry median Cash Ratio is 0.95. ChemoMetec AS's value of 2.29 is 142.3% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #227 out of 834 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #227 out of 834 companies for Cash Ratio. This puts ChemoMetec AS in the upper half of its industry. The industry median Cash Ratio is 0.95. ChemoMetec AS's value of 2.29 is 142.3% above this benchmark. Historically, ChemoMetec AS's own Cash Ratio has ranged from 0.55 to 3.01 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 0.95, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Cash Ratio of 2.29 is 142.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Cash Ratio is 2.29, which is 11% above median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (LTS:0DZ0) is currently considered Fairly Valued. The stock's GF Value™ is kr520.57, compared to a current price of kr517.65 — trading 0.6% below its estimated fair value. The current Cash Ratio is 2.29, which is 11% above median its 10-year median of 2.06 and 142.3% above the Medical Devices & Instruments industry median of 0.95. ChemoMetec AS's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ChemoMetec AS (LTS:0DZ0), the current Cash Ratio is 2.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (LTS:0DZ0) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr517.65 is trading 0.6% below its estimated GF Value™ of kr520.57.
GuruFocus considers ChemoMetec AS to be Fairly Valued.
Key valuation signals for LTS:0DZ0:
Cash Ratio: 2.29 (11% above median its 10-year median of 2.06)
GF Value™: kr520.57 vs. price of kr517.65 (0.6% below fair value)
Industry Position: 142.3% above the Medical Devices & Instruments median (#227 of 834)
No single metric tells the full story. See the LTS:0DZ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
90GF Score
Get the complete analysis for LTS:0DZ0
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DZ0 has been successfully added to your 
